1
|
Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor A, Costello R, Zhang Y, Kurlander RJ, Korde N, Roccaro AM, Ghobrial IM, Landgren O, Calvo KR. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. J Mol Diagn 2015; 17:669-78. [PMID: 26433312 DOI: 10.1016/j.jmoldx.2015.06.006] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Revised: 05/26/2015] [Accepted: 06/22/2015] [Indexed: 12/20/2022] Open
Abstract
The bone marrow (BM) microenvironment of multiple myeloma (MM) is reported to play a role in the biology of disease. In this study, we found that the extracellular BM microenvironment in MM contains a unique miRNA signature detectable by miRNA microarray and quantitative real-time PCR, which is partially represented in the peripheral blood. Eleven miRNAs were significantly decreased in both BM and serum of MM patients in comparison with controls. Evaluation of these miRNAs in plasma of a separate cohort of MM patients and controls confirmed significantly aberrant levels of let-7a, let-7b, let-7i, miR-15b, miR-16, and miR-20a in both serum and plasma. We then studied the myeloma precursor diseases and found that a subset of the MM miRNAs exhibited aberrant expression in monoclonal gammopathy of undetermined significance and smoldering myeloma. miRNA analysis of enriched CD138(+) plasma cells from MM and monoclonal gammopathy of undetermined significance found that most of the validated MM BM signature miRNAs were significantly decreased in MM plasma cells. Gene expression profiling indicated that multiple targets of the decreased miRNAs found increased expression in MM plasma cells, including ATF2, HRAS, HDAC4, TGFB1, TGFBR1, and mitogen-activated protein kinases. The findings suggest that these miRNAs are detectable in aberrant levels in the peripheral blood of patients with plasma cell proliferation and may play a role in aberrant plasma cell proliferation and disease progression.
Collapse
Affiliation(s)
- Weixin Wang
- Hematology Section, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland
| | - Meghan Corrigan-Cummins
- Hematology Section, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland
| | - Emily A Barber
- Hematology Section, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland
| | - Layla M Saleh
- Hematology Section, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland
| | - Adriana Zingone
- Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Azam Ghafoor
- Hematology Section, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland
| | - Rene Costello
- Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Yong Zhang
- Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Roger J Kurlander
- Hematology Section, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland
| | - Neha Korde
- Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Aldo M Roccaro
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Irene M Ghobrial
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
| | - Ola Landgren
- Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Katherine R Calvo
- Hematology Section, Department of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, Maryland.
| |
Collapse
|
2
|
Türkmen S, Binder A, Gerlach A, Niehage S, Theodora Melissari M, Inandiklioglu N, Dörken B, Burmeister T. High prevalence of immunoglobulin light chain gene aberrations as revealed by FISH in multiple myeloma and MGUS. Genes Chromosomes Cancer 2014; 53:650-6. [PMID: 24729354 DOI: 10.1002/gcc.22175] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2013] [Accepted: 03/31/2014] [Indexed: 01/09/2023] Open
Abstract
Multiple myeloma (MM) is a malignant B-cell neoplasm characterized by an uncontrolled proliferation of aberrant plasma cells in the bone marrow. Chromosome aberrations in MM are complex and represent a hallmark of the disease, involving many chromosomes that are altered both numerically and structurally. Nearly half of the cases are nonhyperdiploid and show IGH translocations with the following partner genes: CCND1, FGFR3 and MMSET, MAF, MAFB, and CCND3. The remaining 50% are grouped into a hyperdiploid group that is characterized by multiple trisomies involving chromosomes 3, 5, 7, 9, 11, 15, 19, and 21. In this study, we analyzed the immunoglobulin light chain kappa (IGK, 2p12) and lambda (IGL, 22q11) loci in 150 cases, mostly with MM but in a few cases monoclonal gammopathy of undetermined significance (MGUS), without IGH translocations. We identified aberrations in 27% (= 40 patients) including rearrangements (12%), gains (12%), and deletions (4.6%). In 6 of 18 patients with IGK or/and IGL rearrangements, we detected a MYC rearrangement which suggests that MYC is the translocation partner in the majority of these cases.
Collapse
Affiliation(s)
- Seval Türkmen
- Labor Berlin, Tumorzytogenetik, Berlin, Germany; Institut für Medizinische Genetik und Humangenetik, Charité, CVK, Berlin, Germany
| | | | | | | | | | | | | | | |
Collapse
|
4
|
González D, van der Burg M, García-Sanz R, Fenton JA, Langerak AW, González M, van Dongen JJM, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood 2007; 110:3112-21. [PMID: 17634408 DOI: 10.1182/blood-2007-02-069625] [Citation(s) in RCA: 127] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
Abstract
AbstractThe ability to rearrange the germ-line DNA to generate antibody diversity is an essential prerequisite for the production of a functional repertoire. While this is essential to prevent infections, it also represents the “Achilles heal” of the B-cell lineage, occasionally leading to malignant transformation of these cells by translocation of protooncogenes into the immunoglobulin (Ig) loci. However, in evolutionary terms this is a small price to pay for a functional immune system. The study of the configuration and rearrangements of the Ig gene loci has contributed extensively to our understanding of the natural history of development of myeloma. In addition to this, the analysis of Ig gene rearrangements in B-cell neoplasms provides information about the clonal origin of the disease, prognosis, as well as providing a clinical useful tool for clonality detection and minimal residual disease monitoring. Herein, we review the data currently available on both Ig gene rearrangements and protein patterns seen in myeloma with the aim of illustrating how this knowledge has contributed to our understanding of the pathobiology of myeloma.
Collapse
Affiliation(s)
- David González
- Section of Haemato-Oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, UK
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Rasmussen T, Knudsen LM, Johnsen HE. Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma. Eur J Haematol 2001; 67:296-301. [PMID: 11872077 DOI: 10.1034/j.1600-0609.2001.00559.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE Cyclin D1 dysregulation has been found with varying frequencies in multiple myeloma (MM) and has been suggested to be associated with a poor prognosis. The aim of this study was to investigate the frequency of cyclin D1 dysregulation in patients being treated for MM and to test whether cyclin D1 dysregulation is a prognostic factor for MM patients. METHODS To achieve the above aims we designed a highly sensitive and reproducible real-time reverse-transcription polymerase chain reaction (RT-PCR) assay for quantitation of cyclin D1 mRNA. Using this assay, 110 diagnostic bone marrow (BM) samples from patients with MM were screened for cyclin D1 dysfunction. RESULTS The real-time assay was able to detect the presence of 0.01% cyclin D1 positive cells allowing a safe detection in MM BM samples. In 42% (46/110) of MM BM samples a greater-than-or-equals 3-fold increase in cyclin D1 mRNA was observed compared to the cyclin D1 level in normal BM. In the remaining group of MM patients the cyclin D1 mRNA levels were comparable to normal donors. Follow-up of 76 MM patients showed no significant (P = 0.35) difference in survival between cyclin D1 positive and negative MM patients. In addition, cyclin D1 dysregulation did not correlate with known prognostic factors. CONCLUSION The developed real-time RT-PCR assay for detection of cyclin D1 mRNA levels offers a fast and safe screening for cyclin D1 dysfunction. When a large cohort of MM patients was screened, the cyclin D1 gene was found to be frequently dysregulated, but there was no significant correlation to survival or known prognostic parameters.
Collapse
Affiliation(s)
- T Rasmussen
- Department of Hematology L, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
| | | | | |
Collapse
|
6
|
Otsuki T, Wada H, Nakazawa N, Taniwaki M, Kouguchi K, Ohkura M, Uehira K, Isoda K, Yata K, Sakaguchi H, Yawata Y, Ueki A, Yamada O. Establishment of CD7+ human myeloma sister cell lines, KMS-21-PE and KMS-21-BM, carrying t(11;14) and t(8;14). Leuk Lymphoma 2001; 42:761-74. [PMID: 11697507 DOI: 10.3109/10428190109099339] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Two new human myeloma cell lines were established from pleural effusion and bone marrow malignant cells derived from a single patient, who manifested hyperammonemia associated with multiple myeloma, and these were characterized. Both lines possess t(11;14)(q13;q32) and t(8;14)(q24;q32) reciprocal translocations and overexpress cyclin D1, but not c-myc. Human myeloma lines including these new lines produced and secreted excess ammonia into culture medium more than non-myelomatous hematological cell lines. In addition, these two lines were revealed to have high surface CD7 expression correlated with relatively high mRNA expression by MP-RT-PCR. Among 8 human myeloma lines, half of them revealed significant surface expression of CD7 and a positive correlation between expression levels of protein and message. CD7 message was also detected in surface negative lines. Consequently, there may be posttranslational regulation of the CD7 molecule, whose cellular biological role in expressing cells has not been elucidated.
Collapse
MESH Headings
- Adult
- Ammonia/metabolism
- Antigens, CD7/metabolism
- Bone Marrow Cells/pathology
- Chromosomes, Human, Pair 11
- Chromosomes, Human, Pair 14
- Chromosomes, Human, Pair 8
- Cyclin D1/metabolism
- Humans
- Hyperammonemia/etiology
- Hyperammonemia/pathology
- Male
- Multiple Myeloma/complications
- Multiple Myeloma/genetics
- Multiple Myeloma/pathology
- Pleural Effusion, Malignant/pathology
- Proto-Oncogene Proteins c-myc/metabolism
- Translocation, Genetic
- Tumor Cells, Cultured/cytology
- Tumor Cells, Cultured/immunology
- Tumor Cells, Cultured/metabolism
Collapse
Affiliation(s)
- T Otsuki
- Department of Hygiene, Kawasaki Medical School, Kurashiki, Okayama, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Fonseca R, Hoyer JD, Aguayo P, Jalal SM, Ahmann GJ, Rajkumar SV, Witzig TE, Lacy MQ, Dispenzieri A, Gertz MA, Kyle RA, Greipp PR. Clinical significance of the translocation (11;14)(q13;q32) in multiple myeloma. Leuk Lymphoma 1999; 35:599-605. [PMID: 10609798 DOI: 10.1080/10428199909169625] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The most common chromosomal translocation in multiple myeloma (MM) is t(11;14)(q13;q32). Here, we describe the clinical characteristics of patients with MM who have this translocation. We have identified 24 patients at our institution who had t(11;14)(q13;q32) as determined by standard cytogenetic analysis (CC). Seven patients had the translocation detected at the time of original diagnosis and 17 at the time of relapse. Median survival in all patients after original diagnosis was 43 months; median survival after the translocation was detected was 11.9 months. Four patients had a clinical diagnosis of plasma cell leukemia. Most patients had an elevated beta2-microglobulin (13/20 had >4 microg/ml). The bone marrow (BM) labeling index (LI) of patients, at the time of translocation detection, was elevated in most (median 1.4%, 17/23 patients had BMLI > or = 1%). Of the 24 patients, 19 (79%) died of disease progression and 5 (21%) were alive with disease at last follow-up. Lytic lesions, bone pain, or compression fractures eventually developed in all patients. Patients with MM who have t(11;14)(q13;q32) detected by standard cytogenetics seem to have an aggressive clinical course.
Collapse
MESH Headings
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Biomarkers, Tumor/analysis
- Blood Cell Count
- Calcium/blood
- Chromosomes, Human, Pair 11/genetics
- Chromosomes, Human, Pair 11/ultrastructure
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 14/ultrastructure
- Creatinine/blood
- Disease Progression
- Follow-Up Studies
- Hemoglobins/analysis
- Humans
- Leukemia, Plasma Cell/genetics
- Leukemia, Plasma Cell/mortality
- Leukemia, Plasma Cell/pathology
- Multiple Myeloma/drug therapy
- Multiple Myeloma/genetics
- Multiple Myeloma/mortality
- Multiple Myeloma/pathology
- Neoplastic Cells, Circulating
- Prognosis
- Survival Analysis
- Translocation, Genetic
- beta 2-Microglobulin/analysis
Collapse
Affiliation(s)
- R Fonseca
- Division of Hematology and Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|